logo
At Least 750 US Hospitals Faced Disruptions During Last Year's CrowdStrike Outage, Study Finds

At Least 750 US Hospitals Faced Disruptions During Last Year's CrowdStrike Outage, Study Finds

WIRED2 days ago
Jul 19, 2025 11:54 AM Of those, more than 200 appear to have had outages of services related to patient care following CrowdStrike's disastrous crash, researchers have revealed. Photograph:When, one year ago today, a buggy update to software sold by the cybersecurity firm CrowdStrike took down millions of computers around the world and sent them into a death spiral of repeated reboots, the global cost of all those crashed machines was equivalent to one of the worst cyberattacks in history. Some of the various estimates of the total damage worldwide have stretched well into the billions of dollars.
Now a new study by a team of medical cybersecurity researchers has taken the first steps toward quantifying the cost of CrowdStrike's disaster not in dollars, but in potential harm to hospitals and their patients across the US. It reveals evidence that hundreds of those hospitals' services were disrupted during the outage, and raises concerns about potentially grave effects to patients' health and well-being.
Researchers from the University of California San Diego today marked the one-year anniversary of CrowdStrike's catastrophe by releasing a paper in JAMA Network Open, a publication of the Journal of the American Medical Association Network, that attempts for the first time to create a rough estimate of the number of hospitals whose networks were affected by that IT meltdown on July 19, 2024, as well as which services on those networks appeared to have been disrupted.
A chart showing a massive spike in detected medical service outages on the day of CrowdStrike's crashes. Courtesy of UCSD and JAMA Network Open
By scanning internet-exposed parts of hospital networks before, during, and after the crisis, they detected that at minimum 759 hospitals in the US appear to have experienced network disruption of some kind on that day. They found that more than 200 of those hospitals seemed to have been hit specifically with outages that directly affected patients, from inaccessible health records and test scans to fetal monitoring systems that went offline. Of the 2,232 hospital networks they were able to scan, the researchers detected that fully 34 percent of them appear to have suffered from some type of disruption.
All of that indicates the CrowdStrike outage could have been a 'significant public health issue,' argues Christian Dameff, a UCSD emergency medicine doctor and cybersecurity researcher, and one of the paper's authors. 'If we had had this paper's data a year ago when this happened," he adds, 'I think we would have been much more concerned about how much impact it really had on US health care.'
CrowdStrike, in a statement to WIRED, strongly criticized the UCSD study and JAMA's decision to publish it, calling the paper 'junk science.' They note that the researchers didn't verify that the disrupted networks ran Windows or CrowdStrike software, and point out that Microsoft's cloud service Azure experienced a major outage on the same day, which may have been responsible for some of the hospital network disruptions. 'Drawing conclusions about downtime and patient impact without verifying the findings with any of the hospitals mentioned is completely irresponsible and scientifically indefensible,' the statement reads.
'While we reject the methodology and conclusions of this report, we recognize the impact the incident had a year ago,' the statement adds. 'As we've said from the start, we sincerely apologize to our customers and those affected and continue to focus on strengthening the resilience of our platform and the industry.'
In response to CrowdStrike's criticisms, the UCSD researchers say they stand by their findings. The Azure outage that CrowdStrike noted, they point out, began the previous night and affected mostly the central US, while the outages they measured began at roughly midnight US east coast time on July 19—about the time when CrowdStrike's faulty update began crashing computers—and affected the entire country. (Microsoft did not immediately respond to a request for comment.) 'We are unaware of any other hypothesis that would explain such simultaneous geographically-distributed service outages inside hospital networks such as we see here' other than CrowdStrike's crash, writes UCSD computer science professor Stefan Savage, one of the paper's co-authors, in an email to WIRED. (JAMA declined to comment in response to CrowdStrike's criticisms.)
In fact, the researchers describe their count of detected hospital disruptions as only a minimum estimate, not a measure of the real blast radius of CrowdStrike's crashes. That's in part because the researchers were only able to scan roughly a third of America's 6,000-plus hospitals, which would suggest that the true number of medical facilities affected may have been several times higher.
The UCSD researchers' findings stemmed from a larger internet-scanning project they call Ransomwhere?, funded by the Advance Research Projects Agency for Health and launched in early 2024 with the intention of detecting hospitals' ransomware outages. As a result of that project, they were already probing US hospitals using the scanning tools ZMap and Censys when CrowdStrike's July 2024 calamity struck.
For the 759 hospitals in which the researchers detected that a service was knocked offline on July 19, their scans also allowed them to analyze which specific services appeared to be down, using publicly available tools like Censys and the Lantern Project to identify different medical services, as well as manually checking some web-based services they could visit. They found that 202 hospitals experienced outages of services directly related to patients. Those services included staff portals used to view patient health records, fetal monitoring systems, tools for remote monitoring of patient care, secure document transfer systems that allow patients to be transferred to another hospital, 'pre-hospital' information systems like the tools that can share initial test results from an ambulance to an emergency room for patients requiring time-critical treatments, and the image storage and retrieval systems that are used to make scan results available to doctors and patients.
'If a patient was having a stroke and the radiologist needed to look at a scan image quickly, it would be much harder to get it from the CT scanner to the radiologist to read,' Dameff offers as one hypothetical example.
The researchers also found that 212 hospitals had outages of 'operationally relevant' systems like staff scheduling platforms, bill payment systems, and tools for managing patient wait times. In another category of 'research relevant' services, the study found that 62 hospitals faced outages. The biggest fraction of outages in the researchers' findings was an 'other' category that included offline services that the researchers couldn't fully identify in their scans at 287 hospitals, suggesting that some of those, too, might have been uncounted patient-relevant services.
'Nothing in this paper says that someone's stroke got misdiagnosed or there was a delay in the care of someone getting life-saving antibiotics, for instance. But there might have been,' says Dameff. 'I think there's a lot of evidence of these types of disruptions. It would be hard to argue that people weren't impacted at a potentially pretty significant level.'
The study's findings give a sprawling new sense of scope to anecdotal reports of how CrowdStrike's outage affected medical facilities that already surfaced over the last year. WIRED reported at the time that Baylor hospital network, a major nonprofit health care system, and Quest Diagnostics were both unable to process routine bloodwork. The Boston-area hospital system Mass General Brigham reportedly had to bring 45,000 of its PCs back online, each of which required a manual fix that took 15 to 20 minutes.
In their study, researchers also tried to roughly measure the length of downtime of the hospital services affected by the CrowdStrike outage, and found that most recovered relatively quickly: About 58 percent of the hospital services were back online within six hours, and only 8 percent or so took more than 48 hours to recover.
That's a far shorter disruption than the outages from actual cyberattacks that have hit hospitals, the researchers note: Mass-spreading malware attacks like NotPetya and WannaCry in 2017 as well as the Change Healthcare ransomware attack that struck the payment provider subsidiary of United Healthcare in early 2024 all shut down scores of hospitals across the US—or in the case of WannaCry, the United Kingdom—for days or weeks in some cases. But the effects of the CrowdStrike debacle nonetheless deserve to be compared to those intentionally inflicted digital disasters for hospitals, the researchers argue.
'The duration of the downtimes is different, but the breadth, the number of hospitals affected across the entire country, the scale, the potential intensity of the disruption is similar,' says Jeffrey Tully, a pediatrician, anesthesiologist, and cybersecurity researcher who coauthored the study.
A map showing the duration of the apparent downtime of detected medical service outages in hospitals across the US. Courtesy of UCSD and JAMA Network Open
A delay of hours, or even minutes, can increase mortality rates for heart attack and stroke patients, says Josh Corman, a cybersecurity researcher with a focus on medical cybersecurity at the Institute for Security and Technology and former CISA staffer who reviewed the UCSD study. That means that even a shorter-duration outage in patient related services across hundreds of hospitals could have concrete and seriously harmful—if hard to measure—consequences.
Aside from drawing a first estimate of the possible toll on patients' health in this single incident, the UCSD team emphasizes that the real work of their study is to show that, with the right tools, it's possible to monitor and learn from these mass medical network outages. The result may be a better sense of how to prevent—or in the case of more intentional downtime from cyberattacks and ransomware—protect hospitals from experiencing them in the future.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cell‑Based Assays Report 2025: Key Market Drivers, Tech Trends & Competitive Landscape to 2030
Cell‑Based Assays Report 2025: Key Market Drivers, Tech Trends & Competitive Landscape to 2030

Yahoo

time19 minutes ago

  • Yahoo

Cell‑Based Assays Report 2025: Key Market Drivers, Tech Trends & Competitive Landscape to 2030

The global cell-based assays market is set to grow from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, marking a CAGR of 9.1%. This surge is fueled by the rising demand in drug discovery and increased R&D investments by the pharmaceutical and biotech industries. The prevalence of cancer is boosting the need for advanced therapies, while the growth of cell-based assays applications in chronic diseases and personalized medicine further propels market expansion. In 2024, the drug discovery and flow cytometry segments dominated the market. The US, with its strong healthcare infrastructure and biopharmaceutical industry, led the global market. Key companies in this sector include BD, Thermo Fisher Scientific, and Merck KGaA. Cell Based Assays Market Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Cell Based Assays Market by Offering (Consumables (Reagents, Assay Kits, Cell Lines, Microplates, Probes, Labels), Instruments & Software), Technology (Flow Cytometry, HTS), Application (Drug Discovery (Toxicity, PK/PD Studies)) - Global Forecast to 2030" has been added to global cell-based assays market is anticipated to expand from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.1%. This growth is fueled by escalating demand in drug discovery and the increasing need for sophisticated therapies, particularly in oncology. An uptick in research and development investments from pharmaceutical and biotechnology firms is another catalyst propelling market expansion. Drug Discovery's Dominance in Applications Within the applications segment, drug discovery is poised to retain its prominence through 2024. It encompasses subcategories such as toxicity, pharmacokinetics, and pharmacodynamics studies. The segment's ascendancy is largely attributed to the burgeoning incidence of cancer, which heightens demand for novel therapies. Additionally, robust investments and the emergence of contract research organizations are significantly advancing drug discovery efforts. Flow Cytometry Leads Technological Innovations In 2024, the flow cytometry segment emerged as a leader within the technology category, driven by its pivotal role in providing comprehensive cell-based assay measurements. Enhanced adoption of cutting-edge technologies for cell analysis continues to bolster this sector, ensuring its sustained growth trajectory. Regional Insights and U.S. Market Leadership The U.S. held a commanding position in the North American market in 2024, attributed to its stature as the largest biopharmaceutical hub globally. This leadership is strengthened by significant research investments and a robust healthcare framework. The emphasis on developing advanced cell-based therapies is a key driver in response to rising cancer cases. Notable Market Players: BD (US) Thermo Fisher Scientific Inc. (US) Danaher Corporation (US) Merck KGaA (Germany) Agilent Technologies, Inc. (US) Lonza (Switzerland) Charles River Laboratories (US) Bio-Rad Laboratories, Inc. (US) REVVITY (US) Sartorius AG (Germany) And others Research Coverage and Market Insights: The report categorizes the cell-based assays market based on offerings, technology, applications, end users, and regions. It elucidates major drivers, restraints, opportunities, and challenges influencing market dynamics. Additionally, a comprehensive analysis of key industry players, including product launches, collaborations, and acquisitions, sheds light on the competitive landscape. Key Insights for Stakeholders: Drivers such as increasing demand for drug discovery, rising prevalence of cancer, and heightened R&D investments. Constraints involving high costs and licensing restrictions. Opportunities in chronic diseases and personalized medicine sectors. Competitive assessment of major players highlighting their strategies and market positioning. Key Attributes: Report Attribute Details No. of Pages 449 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $17.84 Billion Forecasted Market Value (USD) by 2030 $27.55 Billion Compound Annual Growth Rate 9.1% Regions Covered Global Key Topics Covered: Market Dynamics Drivers Growing Demand For Drug Discovery & Development and Increasing Preference For Cell-Based Assays in Drug Discovery Government Support and Funding For Cell-Based Research Growing Efforts To Curtail Animal-Based Studies Rising Prevalence of Cancer Alliances To Accelerate Innovations in Drug Discovery Restraints High Cost of Instruments and Restrictions Imposed by Product End-User Licenses For Reagents Lack of Standardization of Protocols Used in Cell-Based Assays Opportunities Growing Applications of Cell-Based Assays in Chronic Diseases and Personalized Medicine Growth Opportunities in Emerging Economies Rising Adoption of AI in Drug Discovery and Cell Analysis Challenges Complexities in Assay Designs Shortage of Skilled Professionals Company Profiles Danaher Thermo Fisher Scientific Inc. Merck Kgaa BD Agilent Technologies, Inc. Lonza Eurofins Scientific Charles River Laboratories Bio-Rad Laboratories, Inc. Revvity Sartorius Ag Corning Incorporated Promega Corporation Cell Signaling Technology, Inc. Enzo Biochem Inc. Carna Biosciences, Inc. Intertek Group Plc Bico Cell Biolabs, Inc. Reaction Biology AAT Bioquest, Inc. Pestka Biomedical Laboratories, Inc. Neuromics BPS Bioscience, Inc. Bellbrook Labs Profacgen Bmg Labtech Gmbh Hanugen Therapeutics Altogen Labs Bioagilytix Labs For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Based Assays Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SpaceX is set to launch from Cape Canaveral on Monday
SpaceX is set to launch from Cape Canaveral on Monday

Yahoo

timean hour ago

  • Yahoo

SpaceX is set to launch from Cape Canaveral on Monday

SpaceX plans a Falcon 9 launch of the SESO3b mPOWERmission rocket from Cape Canaveral Space Force Station on Monday afternoon. The launch window for the SpaceX mission opens Monday AT 5:12 p.m. and will remain open for two hours. In case of any delays or issues, a backup launch window is available on Tuesday at the same time. SpaceX Said this will be the sixth flight for the first stage booster supporting this mission. Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live. Solve the daily Crossword

Breast Growth: Cancer or Coincidence in 42-Year-Old?
Breast Growth: Cancer or Coincidence in 42-Year-Old?

Medscape

timean hour ago

  • Medscape

Breast Growth: Cancer or Coincidence in 42-Year-Old?

A 42-year-old woman presented with an atypical enlarging breast mass over the course, which initially raised suspicion of a serious condition but resolved spontaneously. Initial physical examination revealed skin ulcerations and nipple retraction, raising suspicion for inflammatory breast cancer. Biopsy revealed acute and chronic inflammation, granulation-type tissue, and focal granuloma with suppuration, but no evidence of malignancy. With the diagnosis still unclear, the patient was asked to return within 1 month. However, upon her return, the breast mass and positive axillary lymph node had decreased in size significantly, with ulcerated areas showing signs of healing. The case reported by Junisha Martin, a medical student at Ross University School of Medicine in Miami, highlighted the importance of considering a wide range of potential diagnoses. The Patient and Her History The patient with no significant past medical history presented with an enlarging 4.5 cm mass over 2.5 months in the right breast. The patient disclosed that 2 years ago, she had experienced a lemon-sized lump in her right breast that had persisted for approximately 2 months. The mass was accompanied by small superficial ulcerations on the overlying skin and occasional discomfort. The mass completely resolved during that time, and no medical treatment was sought. Six months later, the mass returned to the same location and increased in size, with ulcerations in the areolar region. The patient declined to undergo mammography during that time because of the discomfort of the areolar lesion. The past surgical history consisted of three prior caesarean sections. The patient denied any allergies, smoking, recent travel, pets at home, or use of topical creams and ointments on the affected area. The patient denied any significant family or social history. Findings and Diagnosis On admission, patient vitals were obtained and reported normal: temperature 36.8 °C, blood pressure 132/88 mm Hg, heart rate 84 beats/min, respiratory rate 19 breaths/min, and oxygen saturation 99% on room air. She was alert and in no acute distress on physical examination. Physical examination revealed that the large right breast mass had decreased in size significantly. The mass now measured 3 cm from 4.5 cm and was non-tender, with minimal nipple retraction and healing ulcerations and scars with improving skin discoloration. The patient was scheduled for an ultrasound-guided core biopsy of the right breast and right axillary lymph node due to a high suspicion of malignancy, instead of fine-needle aspiration cytology. A core biopsy of the right breast at 12:00 revealed acute and chronic inflammation, granulation-type tissue, and focal granuloma with suppuration. Immunohistochemical tests were negative for carcinoma. A right axillary lymph node biopsy revealed sinus histiocytosis and acute non-specific lymphadenitis but no evidence of malignancy. During the follow-up visit after 1 week, the patient reported feeling well, with mild soreness at the biopsy site. Repeated physical examinations were consistent with an enlarging areolar breast mass with skin ulcerations and nipple retraction. The right breast was moderately tender on palpation. Due to the discordance between the pathology report and physical examination, a repeat ultrasound-guided biopsy was recommended for further management. No medications were prescribed to the patient, and conservative measures were taken because the final diagnosis was not confirmed. Upon repeat biopsy, physical examination revealed that the large right breast mass had decreased in size significantly. The decreasing size of the lesion (mass effect), decreasing size of the lymph node, and the nature of the ulcer now healing ruled out inflammatory breast cancer, and the physician suspected an idiopathic aetiology, instead of an inflammatory or infectious cause of this patient's presentation. A multidisciplinary approach was established for the patient, with a primary care physician and surgeon for further management if there were signs of disease progression. Discussion 'This case illustrates the diagnostic challenges of inflammatory breast lesions with overlapping clinical presentations. While initial findings suggested inflammatory breast cancer, biopsy results were negative for malignancy, pointing towards a benign inflammatory or infectious aetiology, such as idiopathic granulomatous mastitis or cat scratch disease. The spontaneous improvement after conservative management provided further evidence against a malignant process. This case reinforces the need for interdisciplinary collaboration, and further research into inflammatory breast pathologies is vital. Maintaining an open perspective and integrating all available data are essential when evaluating breast masses, facilitating timely diagnosis, and preventing unnecessary aggressive treatments. This case concluded without a definitive diagnosis, highlighting the importance of flexible management guided by clinical improvement in complex presentations,' the authors wrote.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store